Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation

Seminars in Radiation Oncology

Volumn 12, Issue 1 SUPPL. 1, 2002, Pages 59-61

  Arquette, Matthew ^a,b,c   Wasserman, Todd ^a,b,c   Govindan, Ramaswamy ^a,b,c   Garfield, David ^a,b,c   Senzer, Neil ^a,b,c   Gillenwater, Heidi ^a,b,c   Socinski, Mark ^a,b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS MUCOSA; HUMAN; HYPOTENSION; LUNG SMALL CELL CANCER; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036130115     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2002.31375     Document Type: Conference Paper

References (9)

1. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B study 8083
2. Concurrent cisplatin, prolonged oral etoposide and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229)
3. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
4. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial
5. Assessment of the protective effect of amifostine on radiation induced pulmonary toxicity
6. A randomized phase III trial of radiation ± amifostine in patients with advanced stage lung cancer
7. Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage non-small cell lung cancer
8. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC)
9. Randomized doubleblind study of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer (NSCLC)